GlycoNet is a one-stop global destination focused on developing new carbohydrate-based drugs, vaccines and diagnostics, in collaboration with academic and industry organizations to address areas of unmet need through applied glycomics research. This national platform supports translational research, protection of intellectual property, novel drug development, company formation and training of a new generation of glyco-scientists and entrepreneurs. The network includes over 170 researchers across Canada who focus on cancer, chronic diseases, infectious diseases, and neurodegenerative diseases.
GlycoNet is funded by the Government of Canada through the Networks of Centres of Excellence (NCE) Program.
From offering policy advice to sharing his expertise on COVID-19 with the media and public, Dr. Donald Sheppard is recognized a role model with his achievement in engaging with the broader community
Genetic disease research has benefitted substantially from the study of glycomics, which relates to the functions of glycans, or sugar, in biological systems
Canadian Glycomics Network
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
© CANADIAN GLYCOMICS NETWORK (GLYCONET). ALL RIGHTS RESERVED.